Five doses of ABT-089 for ADHD in adults
About this title
Read the official source — NCT00391729Researchers compared ABT-089 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Understand this study
What did researchers investigate?
Researchers compared ABT-089 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Mesa and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 221
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00391729
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Mesa · Lafayette · Oceanside
20 more locations
- San Diego
- Denver
- Jacksonville
- Maitland
- Miami
- Tampa
- Newton
- Farmington Hills
- Omaha
- Bridgewater
- New York
- Staten Island
- Chapel Hill
- Lyndhurst
- Portland
- Charleston
- Memphis
- Lake Jackson
- Herndon
- Middleton
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared ABT-089 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is Abbott.
Did this study involve medication?
Yes. The study involved medication, including ABT-089 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
